Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3497 - Patterns of Germline and Somatic Mutations in 16 Mismatch Repair associated genes analyzed with Next Generation Sequencing(NGS) in Colorectal Cancer with EMAST(+) and/or MSI-high

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Shin-Ching Chang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

S. Chang1, P. Lin2, C. Lin1, J. Lin3, Y. Lan1, J. Jiang3, S. Yang1, C. Lin4, W. Chen1

Author affiliations

  • 1 Surgery, Taipei Veterans General Hospital, 11217 - Taipei/TW
  • 2 Department Of Clinical Pathology, Taipei City Hospital, 112 - Taipei/TW
  • 3 Taipei Veterans General Hospital, Department of Surgery, 112 - Taipei/TW
  • 4 Division Of Genomic Medicine, National Health Research Institutes, 11217 - Taipei/TW
More

Abstract 3497

Background

We assume that besides mismatch repair (MMR) genes, next generation sequencing (NGS) of MMR associated genes could improve detection of driver mutattors and clarify the somatic mutation patterns of subtypes CRC classfied by EMAST and MSI-high.

Methods

Extracted from a 1505 CRC cases database,81 cases with MSI-high and EMAST+,78 cases with EMAST+ and MSS, and 72 cases with MSI-high but EMAST- were identified. The tumor and WBC DNA were applied and got from Biobank of Taipei-Veteran General Hospital afer approval of IRB. The germline and somatic mutations were analyzied with 16- genes NGS (illumina HiSeq2500 system).

Results

Totally 284 pathological germline mutations were identified in 161 patients with MSI-high or EMAST+. The most common gene mutations were EPCAM (17.3%), MSH6 (16.9%), followed by MLH1 (15.2%), and AXIN2(15.2%). Majority of EMAST and MSI resulted from not only MMR dysfunction, but also germline mutations of AXIN2, POLD1 and TGFBR2. After deduction of 284 germline mutations, there were 1,090 somatic mutations in 161 cases with germline mutations, 445 mutations in 70 cases without germline mutations. Tumors with EMAST+ and MSI-high had signifcantly higher mutation number than those of tumors with only EMAST+ or only MSI-high. Besides germline mutations of AXIN2, germline mutations of other genes were similar. With AXIN2 germline mutations, somatic mutation rate was 187.7 ± 97.8 mut/MB significantly higher than those of without germline mutations (137.8± 84.5 mut/MB p = 0.002). Besides five major MMR genes, Eleven Axin2, eight POLE and six TGFbR2 germline mutations resulted in following MSI-high or EMAST (+) genotype without other accompany germline mutation. Clinically, patients with germline mutation had significantly higher frequency of proximal tumor location and early stage disease.

Conclusions

Our result showed that NGS could enhance detection of familial CRC. Somatic mutation burden might be through MSI or EMAST but not only germline mutation genes themselves. Several genes with germline mutations could explain origin of the familiar CRC. AXIN2 gene deserved to do futher experiment to confirm its role in WNT pathway and as a hypermutator.

Clinical trial identification

Legal entity responsible for the study

The Institutional Review Board of Taipei Veterans General Hospital (number 2017-06-004BC).

Funding

Taipei-Veterans General Hospital, Taiwan.

Editorial Acknowledgement

NIL

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.